Published in Blood on March 15, 2005
Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood (2007) 2.70
Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood (2008) 2.50
Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost (2011) 1.91
B cells "transduced" with TAT-fusion proteins can induce tolerance and protect mice from diabetes and EAE. Clin Immunol (2011) 1.44
Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood (2012) 1.38
Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood (2010) 1.32
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol (2013) 1.31
Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells. Blood (2014) 1.25
Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX. Blood (2006) 1.24
B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells. Mol Ther (2010) 1.17
Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice. Blood (2008) 1.17
Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clin Immunol (2011) 1.14
Progress toward inducing immunologic tolerance to factor VIII. Blood (2013) 1.10
Animal models of hemophilia. Prog Mol Biol Transl Sci (2012) 1.04
Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells. Mol Ther (2014) 0.98
Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther (2010) 0.98
Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood (2010) 0.98
B cells induce tolerance by presenting endogenous peptide-IgG on MHC class II molecules via an IFN-gamma-inducible lysosomal thiol reductase-dependent pathway. J Immunol (2008) 0.97
A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood (2009) 0.97
Role of regulatory T cells in tolerance to coagulation factors. J Thromb Haemost (2009) 0.94
Development of Gene Transfer for Induction of Antigen-specific Tolerance. Mol Ther Methods Clin Dev (2014) 0.93
B-Cell Gene Therapy for Tolerance Induction: Host but Not Donor B-Cell Derived IL-10 is Necessary for Tolerance. Front Microbiol (2011) 0.90
Toll-like receptor 4-activated B cells out-compete Toll-like receptor 9-activated B cells to establish peripheral immunological tolerance. Proc Natl Acad Sci U S A (2012) 0.89
Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice. Blood (2012) 0.88
Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis. Semin Arthritis Rheum (2008) 0.88
Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells. Mol Ther (2012) 0.86
Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation. Br J Haematol (2011) 0.86
Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Rev Hematol (2010) 0.85
B-cell delivered gene therapy for tolerance induction: role of autoantigen-specific B cells. J Autoimmun (2010) 0.84
Gene therapy for immune tolerance induction in hemophilia with inhibitors. J Thromb Haemost (2016) 0.84
Factor VIII delivered by haematopoietic stem cell-derived B cells corrects the phenotype of haemophilia A mice. Thromb Haemost (2011) 0.82
Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts. Mol Ther (2009) 0.82
Advances in Overcoming Immune Responses following Hemophilia Gene Therapy. J Genet Syndr Gene Ther (2011) 0.81
Tolerance to MHC class II disparate allografts through genetic modification of bone marrow. Gene Ther (2012) 0.81
CD8+ regulatory T cells are responsible for GAD-IgG gene-transferred tolerance induction in NOD mice. Immunology (2008) 0.81
Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood (2016) 0.81
Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cell Immunol (2015) 0.80
Immunology: Oral solutions. Nature (2014) 0.80
Profile of efraloctocog alfa and its potential in the treatment of hemophilia A. J Blood Med (2015) 0.79
Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J Leukoc Biol (2013) 0.79
Engineering less immunogenic and antigenic FVIII proteins. Cell Immunol (2015) 0.79
Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance. Expert Rev Hematol (2014) 0.79
In vivo induction of regulatory T cells for immune tolerance in hemophilia. Cell Immunol (2015) 0.78
Inhibitors - cellular aspects and novel approaches for tolerance. Haemophilia (2014) 0.77
FVIII-specific human chimeric antigen receptor (CAR) T-regulatory cells suppress T-and B-cell responses to FVIII. Blood (2016) 0.75
Induction of Hematopoietic Microchimerism by Gene-Modified BMT Elicits Antigen-Specific B and T Cell Unresponsiveness toward Gene Therapy Products. Front Immunol (2016) 0.75
Repression of Factor VIII Inhibitor Development with Apoptotic Factor VIII-expressing Embryonic Stem Cells. Hematol Rep (2013) 0.75
Immune tolerance induced by platelet-targeted Factor VIII gene therapy in hemophilia A mice is CD4 T cell-mediated. J Thromb Haemost (2017) 0.75
B cells turn off virgin but not memory T cells. Science (1992) 4.12
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet (1995) 3.74
Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med (1992) 3.52
Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh (1975) 2.10
Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood (2000) 1.36
Tolerogenicity of resting and activated B cells. J Exp Med (1994) 1.25
Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest (2000) 1.22
Role of B7 in T cell tolerance. J Immunol (2004) 1.21
Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost (2004) 1.17
Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis (2004) 1.17
Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J Immunol (2000) 1.17
Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. Proc Natl Acad Sci U S A (1999) 1.15
Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol (2002) 1.15
Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood (2004) 1.10
Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood (2000) 1.09
Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood (2003) 1.09
Genetically transferred central and peripheral immune tolerance via retroviral-mediated expression of immunogenic epitopes in hematopoietic progenitors or peripheral B lymphocytes. Mol Med (1997) 1.04
Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-beta? Gene Ther (2004) 1.02
A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. Clin Immunol (2004) 1.01
Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol (2000) 0.95
The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost (2003) 0.95
Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood (2001) 0.90
Factor VIII alloantibodies in hemophilia. Curr Opin Hematol (2004) 0.82
Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. J Biol Chem (2002) 0.82
High-throughput optimization of protein expression in the baculovirus system based on determination of relative expression efficiency of viral stocks. Anal Biochem (2004) 0.81
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol (2012) 3.59
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood (2008) 2.50
Arf6 and microtubules in adhesion-dependent trafficking of lipid rafts. Nat Cell Biol (2007) 2.23
Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol (2011) 1.91
Immunogenicity of protein therapeutics. Trends Immunol (2007) 1.90
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol (2011) 1.86
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood (2013) 1.84
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood (2014) 1.64
Identification of an essential Francisella tularensis subsp. tularensis virulence factor. Infect Immun (2008) 1.50
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood (2012) 1.49
B cells "transduced" with TAT-fusion proteins can induce tolerance and protect mice from diabetes and EAE. Clin Immunol (2011) 1.44
Simple quality improvement interventions reduce unnecessary intravascular device dwell time. Infect Control Hosp Epidemiol (2008) 1.40
Robust Fitting of a Weibull Model with Optional Censoring. Comput Stat Data Anal (2013) 1.39
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood (2014) 1.26
Francisella tularensis subsp. tularensis Schu S4 disulfide bond formation protein B, but not an RND-type efflux pump, is required for virulence. Infect Immun (2008) 1.23
Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost (2004) 1.17
B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells. Mol Ther (2010) 1.17
RalA-exocyst complex regulates integrin-dependent membrane raft exocytosis and growth signaling. Curr Biol (2009) 1.16
Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol (2002) 1.15
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood (2013) 1.15
Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clin Immunol (2011) 1.14
Endothelial surface N-glycans mediate monocyte adhesion and are targets for anti-inflammatory effects of peroxisome proliferator-activated receptor γ ligands. J Biol Chem (2011) 1.09
Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. Cell Immunol (2006) 1.08
A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. Clin Immunol (2004) 1.01
Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood (2013) 1.00
Tolerance induction by gene transfer to lymphocytes. Curr Gene Ther (2007) 1.00
Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. Genome Biol (2015) 0.99
Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood (2010) 0.98
Mycobacterial Hsp65-IgG-expressing tolerogenic B cells confer protection against adjuvant-induced arthritis in Lewis rats. Arthritis Rheum (2007) 0.97
B cells induce tolerance by presenting endogenous peptide-IgG on MHC class II molecules via an IFN-gamma-inducible lysosomal thiol reductase-dependent pathway. J Immunol (2008) 0.97
Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev (2012) 0.97
A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood (2009) 0.97
In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol (2012) 0.95
Requirement of the CXXC motif of novel Francisella infectivity potentiator protein B FipB, and FipA in virulence of F. tularensis subsp. tularensis. PLoS One (2011) 0.93
A factorial analysis of the combined effects of hydrogel fabrication parameters on the in vitro swelling and degradation of oligo(poly(ethylene glycol) fumarate) hydrogels. J Biomed Mater Res A (2013) 0.93
Mechanisms of gene therapy for tolerance: B7 signaling is required for peptide-IgG gene-transferred tolerance induction. J Immunol (2005) 0.93
Factor VIII inhibitors: risk factors and methods for prevention and immune modulation. Clin Rev Allergy Immunol (2009) 0.92
Tolerance induction via a B-cell delivered gene therapy-based protocol: optimization and role of the Ig scaffold. Cell Immunol (2005) 0.91
B-Cell Gene Therapy for Tolerance Induction: Host but Not Donor B-Cell Derived IL-10 is Necessary for Tolerance. Front Microbiol (2011) 0.90
Toll-like receptor 4-activated B cells out-compete Toll-like receptor 9-activated B cells to establish peripheral immunological tolerance. Proc Natl Acad Sci U S A (2012) 0.89
Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J Diabetes Res (2013) 0.89
Potential application of tregitopes as immunomodulating agents in multiple sclerosis. Neurol Res Int (2011) 0.88
In vivo induction of tolerance by an Ig peptide is not affected by the deletion of FcR or a mutated IgG Fc fragment. Int Immunol (2002) 0.88
B-cell delivered gene transfer of human S-Ag-Ig fusion protein protects from experimental autoimmune uveitis. Clin Immunol (2005) 0.88
Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice. Diabetes (2009) 0.87
Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease. Hum Vaccin Immunother (2012) 0.87
STAT6 controls the number of regulatory T cells in vivo, thereby regulating allergic lung inflammation. J Immunol (2013) 0.85
Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Mol Ther (2013) 0.84
B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphoma. Am J Clin Pathol (2012) 0.84
Bone marrow transplantation combined with gene therapy to induce antigen-specific tolerance and ameliorate EAE. Mol Ther (2005) 0.84
B-cell delivered gene therapy for tolerance induction: role of autoantigen-specific B cells. J Autoimmun (2010) 0.84
Spontaneous diabetes in hemizygous human amylin transgenic mice that developed neither islet amyloid nor peripheral insulin resistance. Diabetes (2008) 0.83
Gene therapy for tolerance and vice versa: a case for hemophilia. Curr Opin Mol Ther (2010) 0.83
The transcription factor E26 transformation-specific sequence-1 mediates neointima formation in arteriovenous fistula. J Am Soc Nephrol (2013) 0.82
Aging and neoteny in the B lineage. Blood (2012) 0.81
Characterization of porous polymethylmethacrylate space maintainers for craniofacial reconstruction. J Biomed Mater Res B Appl Biomater (2013) 0.80
Targeting endothelial adhesion molecule mRNA to control inflammation: novel insights into potential anti-inflammatory effects of IL-19. Focus on "Interleukin-19 decreases leukocyte-endothelial cell interactions by reduction in endothelial cell adhesion molecule mRNA stability". Am J Physiol Cell Physiol (2013) 0.79
B cell receptor signaling mediates immediate protection from Fas-induced apoptosis upstream of caspase activation through an atypical protein kinase C isozyme and de novo protein synthesis. Eur J Immunol (2003) 0.79
Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J Leukoc Biol (2013) 0.79
Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies. Discov Med (2013) 0.78
Gene therapy and bone marrow stem-cell transfer to treat autoimmune disease. Trends Mol Med (2009) 0.77
Transplantation tolerance: one --- step towards the holy grail. Clin Immunol (2010) 0.77
Gene therapy with IgG-HY fusion proteins to reduce male-specific T-cell reactivity in vitro. Hum Gene Ther (2011) 0.76
Tolerance induction via B-cell delivered gene therapy. Methods Mol Biol (2012) 0.76
Cellular Immunology--mission statement. Cell Immunol (2015) 0.75